RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 26, 2004-- Affinergy will be presenting on February 24, 2004 at Medtech Insight's prestigious "Investment In Innovation" event, taking place February 24-25, 2004 at the Hyatt Regency Irvine in Irvine, California Affinergy, Inc., a biomaterial coatings company with unique capabilities to regulate biological processes on the surface of synthetic materials, announced today that it has been selected as a presenting company at the Medtech Insight "Investment In Innovation: A Preview of Early-Stage Medical Technology Companies"(TM) conference, to be held in Irvine, California on February 24-25. The event is the premiere business development, strategic partnering, and investment meeting for medical technology executives.
"Affinergy's technologies can fundamentally improve the performance of products in major segments of the medical device industry," said Peyton Anderson, CEO of Affinergy. "We are excited to have a single forum to present our platform technology to 400 executives of the leading companies in the industry. Affinergy's coatings offer unique product performance benefits for our commercial partners and remarkably flexible application options in the production of the devices."
The Investment In Innovation Conference is a two-day event that will highlight emerging technologies being developed by more than 50 small, mostly privately held medical technology companies seeking partnering and/or investment. The meeting will draw senior executives from the investment community as well as from major medical technology and biopharmaceutical companies.
"Affinergy's proprietary technologies can create a wide array of bioactive surfaces on synthetic materials," said the company's co-founder Daniel J. Kenan MD, Ph.D., of Duke University Medical Center. "We believe our proprietary coatings can significantly improve patient outcomes while reducing healthcare costs. Affinergy allows device companies to create new products, improve existing products, and streamline manufacturing processes through a modular and highly specific coating system unlike any other on the market."
Affinergy, Inc. develops biomaterial coatings that can selectively bond or repel specific materials and regulate biology at the surface of devices implanted into the body. This proprietary and patented technology for surface modification and biomolecule immobilization is called "Interfacial Biomaterials" (IFBM). Applications include: improving bone ingrowth on orthopedic devices such as hip implants, preventing infections/biofilms on catheters and other medical devices, improving blood filters, and "kick-starting" biological processes to grow new arteries. Affinergy's technology was developed at Duke University by Dr. Dan Kenan, M.D., Ph.D. and Dr. Mark Grinstaff, Ph.D.
For more information, visit www.affinergy.com or contact Peyton Anderson at 919-345-4732.
About Medtech Insight
Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Irvine conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail firstname.lastname@example.org, or visit http://www.medtechinsight.com/in3-10.html.
Affinergy, Inc. Peyton Anderson, 919-345-4732 www.affinergy.com
Source: Affinergy, Inc.